Carboplatin + etopside in mCRPC: high toxicity and low efficacy

The results of the French Genito-Urinary Tumor Group (GETUG) P01 trial — a Phase II study of carboplatin and etoposide in men with progressive metastatic castration-resistant prostate cancer (mCRPC) — have shown that this form of combination chemotherapy has limited efficacy and an unacceptably high toxicity in men with late stage prostate cancer. … READ MORE …

The Tuesday news reports: February 24, 2009

We have dealt separately with an article on the way in which surgical technique appears to affect the likelihood of positive surgical margins after robot-assisted laparoscopic prostatectomy (RALP). Other reports today cover:

  • Whether multifocal tumors are “riskier” that single prostate cancer tumors
  • The role of n-3 fatty acids in prevention of selected cancers (including prostate cancer)
  • Lycopene in prevention and treatment of prostate cancer
  • Serum cholesterol levels and prostate cancer
  • Different forms of imaging for prostate cancer localization during EBRT
  • Carboplatin + etopside chemotherapy in late-stage metastatic disease … READ MORE …

The weekend prostate cancer news: Saturday, January 31, 2009

Items covered in this weekend news report include:

  • Acrylamide exposure as a potential risk for prostate cancer
  • The relative merits of three standard first-line therapies in intermediate risk prostate cancer
  • Estramustine + etopside in hormone-refractory prostate cancer (HRPC)
  • Bone turnover markers and risk for skeletal-related events in patients receiving zoledronic acid … READ MORE …